List view / Grid view
Researchers reveal how two genetic variations may contribute to COVID-19 disease severity and suggest the product of one, the CD209 antigen, may be a potential drug target.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
The first comprehensive survey of genomics, transcriptomics, global proteomics and phosphoproteomics has revealed insights into paediatric brain tumours.
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
Scientists have shown how SARS-CoV-2 induces changes in the architecture of host cells to drive replication and made their data available to all.
Scientists suggest the PCSK9Q152H gene variant may act as a “fountain of youth”, allowing people to live longer, healthier lives.
The non-human primate model exhibited a COVID-19-like disease and showed how symptoms and viral activity change over the course of SARS-CoV-2 infection.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
![robotic hand pipetting from petri dish of organoids next to a clock - idea of automation speeding up organoid development [Credit: Daria Sokol/MIPT Press Office].](https://www.drugtargetreview.com/wp-content/uploads/algorithm-accelerating-organoid-development.jpg)
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
Binding of SARS-CoV-2 spike proteins to the brain’s endothelial cells can cause the blood-brain barrier to become leaky, potentially causing the neurological symptoms associated with COVID-19.
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
A new study has highlighted the advantages of using flow cytometry for the analysis of neuroimmune cell populations from mouse models.
A new report has said that by 2023, the flow cytometry market will be worth $8.88 billion, partly due to an increase in stem cell research.
